Motif Bio Plc CEO Dr Graham Lumsden Interview: First Patient dosed

Motif Bio Plc (LON:MTFB) CEO Dr Graham Lumsden talks to DirectorsTalk about the dosing of the first patient in the iclaprim Phase 3 trials to treat skin infections. Graham explains what this for both patients and investors.

 

Motif Bio Plc is a clinical-stage biopharmaceutical company, specialising in the development of novel antibiotics that are designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. Our lead product candidate, iclaprim, is being developed for the treatment of the most common and serious bacterial infections such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains such as MRSA (methicillin-resistant Staphylococcus aureus). Two Phase III ABSSSI clinical trials are on track to be completed in 2H17 and if approved, iclaprim could be ready for commercialisation in 2018. The HABP trial is expected to start 2H16. The Company is in discussions with pharmaceutical companies and universities to build a pipeline of innovative antibiotics targeting Gram-positive and Gram-negative bacteria.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Motif Bio Plc

    More articles like this

    Motif Bio Plc

    Motif Bio plc Proposed Placing to raise approximately £19.4m

    Motif Bio plc (LON:MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announced today its intention to raise approximately £19.4 million (US$25 million), before expenses, by way of a conditional placing with new and

    Motif Bio Plc

    Motif Bio PLC Reports Year-End 2016 Financial Results

    Motif Bio PLC (LON:MTFB), a clinical stage biopharmaceutical company specializing in developing novel antibiotics, today announced financial results for the year ended December 31, 2016. Motif Bio made significant progress in 2016 towards our goal of

    Motif Bio Plc

    Motif Bio plc Update post NASDAQ IPO

    Motif Bio plc (LON:MTFB, NASDAQ:MTFB), is a late clinical stage antibiotic development company. The company completed its IPO on NASDAQ in November last year raising $25m before expenses. With the funds from the IPO the company

    Motif Bio Plc

    Motif Bio plc appoint ex NASDAQ listed Tyme Technologies CFO

    Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, has told DirectorsTalk that Robert Dickey IV has been appointed as Chief Financial Officer. Mr. Dickey is an accomplished financial professional

    Motif Bio Plc

    Motif Bio PLC Update on US Public Offering

    Motif Bio plc (LON:MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, further to its announcement of 9 August 2016, said today that it is continuing to work towards pricing of its proposed public

    Motif Bio Plc

    Motif Bio plc 2 posters at ID Week in New Orleans

    Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, has told DirectorsTalk that it will be presenting two poster studies at IDWeek, October 26 to 30 in New Orleans, USA.

    Motif Bio Plc

    Motif Bio plc progressing trials efficiently with latest update

    Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, has given DirectorsTalk an update to REVIVE-1, one of Motif Bio’s two Phase 3 clinical trials currently enrolling patients with Acute